Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

52.91 (USD) • At close December 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32018 Q22018 Q1
Revenue 48.11840.81327.61413.0761.87115.2772.510015.2770.5390.3381.2422.01733.43200000000
Cost of Revenue 3.2423.0041.6541.2160.3770.3160.2550.410.9120.5220.0338.0140.0650.7371.29700000000
Gross Profit 44.87637.80925.9611.861.49414.9612.2459.6-10.91214.7550.506-7.6761.17521.2832.13500000000
Gross Profit Ratio 0.9330.9260.940.9070.7990.9790.8980.9600.9660.9391.0710.9480.9670.96100000000
Reseach & Development Expenses 12.12812.31912.06613.30512.10512.54612.35610.02810.9129.60312.0818.03810.2097.20416.2617.5877.9911.7371.5120.6970.3990.2250.225
General & Administrative Expenses 058.792065.69530.32420.27515.09614.63311.99410.3767.9466.7726.6716.7945.163.892.151.5260.6060.3870.2340.1120.112
Selling & Marketing Expenses 000-22.690000000000000000000
SG&A 57.9158.79251.57843.00530.32420.27515.09614.63311.99410.3767.9466.7726.6716.7945.163.892.151.5260.6060.3870.2340.1120.112
Other Expenses 000.605-0.013-0.048-0.0470.006-0.05-0.0070.1060.037-0.0050.005-0.039-0.0344.28200000-0.675-0.675
Operating Expenses 70.03871.11163.64456.3142.42932.82127.45224.66122.90619.97920.02714.8116.8813.99821.42111.47710.1413.2632.1181.0840.633-0.338-0.338
Operating Income -25.162-33.302-37.684-44.45-40.935-32.821-24.952-15.061-22.906-5.224-19.521-14.448-15.7057.28210.714-11.477-10.141-3.263-2.118-1.084-0.633-0.338-0.338
Operating Income Ratio -0.523-0.816-1.365-3.399-21.879-2.148-9.981-1.5060-0.342-36.217-42.746-12.6650.3310.3200000000
Total Other Income Expenses Net 1.7420.0121.9532.5481.7871.3971.5331.4620.39-0.519-0.716-0.349-0.333-0.908-0.0250.010.0040.0130.161-0.328-0.0480.0080.008
Income Before Tax -23.42-33.29-35.731-41.902-40.935-31.424-23.419-13.599-22.516-5.743-20.237-14.797-16.0386.37410.689-11.467-10.137-3.25-1.957-1.412-0.681-0.33-0.33
Income Before Tax Ratio -0.487-0.816-1.294-3.204-21.879-2.057-9.368-1.360-0.376-37.545-43.778-12.9340.290.3200000000
Income Tax Expense 00-0.2730.398-1.787-27.078-1.533-0.521-0.0050.5190.0010.054-0.3410.0290.313-0.0010.001000.3280.04800
Net Income -23.42-33.29-35.731-41.902-39.148-31.424-21.886-13.078-22.511-6.262-20.238-14.851-15.6976.34510.376-11.467-10.138-3.25-1.957-1.412-0.681-0.33-0.33
Net Income Ratio -0.487-0.816-1.294-3.204-20.924-2.057-8.754-1.3080-0.41-37.547-43.938-12.6590.2880.3100000000
EPS -0.61-0.88-1.01-1.31-1.28-1.17-0.82-0.49-0.84-0.26-0.98-0.72-0.760.310.51-0.56-0.54-0.3-0.18-0.13-0.063-0.077-0.077
EPS Diluted -0.61-0.88-1.01-1.31-1.28-1.17-0.82-0.49-0.84-0.26-0.98-0.72-0.760.290.47-0.53-0.54-0.3-0.18-0.13-0.063-0.077-0.077
EBITDA -20.675-30.942-34.478-40.566-37.921-30.293-22.48-12.688-21.672-5.107-19.767-14.408-15.8647.40710.778-11.437-10.117-3.246-2.103-1.065-0.624-0.329-0.329
EBITDA Ratio -0.43-0.758-1.365-3.373-21.879-1.994-9.061-1.2980-0.311-35.33-41.574-12.3190.3760.32200000000